Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRicardo PillaiSun, June 21, 2026 at 4:36 PM GMT+2 3 min readIs ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.Ocugen (OCGN) Reports Q1 EPSPressmaster/Shutterstock.comAbsci Corporation (ABSI) is a clinical-stage biopharmaceutical company focused on transforming drug discovery through the use of generative artificial intelligence, positioning itself at the forefront of a rapidly growing trend toward AI-enabled drug development. The company’s lead program, ABS-201, is an antibody-based therapy designed to treat androgenetic alopecia, or pattern hair loss, by targeting a protein pathway involved in hair follicle biology.Read More: 15 AI Stocks That Are Quietly Making Investors RichRead More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside PotentialABS-201 represents a significant milestone for the company, as it has advanced from an AI-designed concept into human clinical testing, demonstrating the practical application of Absci’s technology platform and validating its ability to accelerate the drug development process. Investor enthusiasm is increasingly centered on the ongoing HEADLINE clinical trial, where encouraging early safety data has supported confidence in the program’s potential and highlighted the company’s ability to move candidates into the clinic faster and at a lower cost than traditional biotechnology approaches.Beyond hair loss, Absci’s broader platform offers opportunities across multiple therapeutic areas, including endometriosis, expanding the commercial potential of its pipeline and creating additional avenues for long-term value creation. The company is also benefiting from a broader industry shift as pharmaceutical companies and investors place greater emphasis on platforms capable of shortening development timelines and improving research productivity.This growing recognition of AI-driven drug discovery has strengthened the investment case for Absci, particularly as it continues to generate clinical evidence supporting its technology. With ABS-201 progressing through human trials, a differentiated platform, and exposure to large underserved markets, Absci is positioned to benefit from both advancing clinical milestones and increasing adoption of AI-powered drug development, creating meaningful upside potential if its programs continue to demonstrate favorable results.Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, improving reimbursement adoption, and significant upside from its gene-editing pipeline. CRSP's stock price has appreciated by approximately 28.41% since our coverage. TradersPro shares a similar view but emphasizes on AI-driven drug discovery, with Absci Corporation’s thesis centered on accelerating antibody development and advancing AI-designed therapies into human clinical trials.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info